arrow
M

Maria Giuseppa Vitale

azienda ospedaliero-universitaria of modena
H指数:21
被引数:2,484

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-Term Oncological Outcomes in Metastatic Prostate Cancer Patients Who Are Able to Maintain/Recover Ongoing Anticancer Therapy After SARS-CoV-2 Infection—Results of the MEET-URO 22 Study

SARS-CoV-2感染后能够维持/恢复持续抗肿瘤治疗的转移性前列腺癌患者的长期肿瘤学结局——MEET-URO 22研究的结果

Cancers
IF4.4
2026-01-150
OAAI
A Novel Molecular Profile of Hormone-Sensitive Prostate Cancer Defines High Risk Patients

激素敏感型前列腺癌的新型分子特征定义了高风险患者

2025-02-200
OAAI
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
2024-10-011
OA
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)
2024-09-070
OA
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study

放疗加pembrolizumab治疗晚期尿路上皮癌: 来自ARON-2真实世界研究的结果

2024-08-270
OAAI
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)

一线免疫疗法联合或酪氨酸激酶抑制剂治疗转移性非透明细胞肾细胞癌的前期细胞减灭性肾切除术对现实世界的影响 (来自ARON-1回顾性研究的亚分析)

2024-05-054
OAAI
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study
2022-03-0165
PRE
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

生命晚期的PD-1/PD-L1检查点抑制剂: 来自大型多中心队列的临时分析

2021-06-2415
OAAI
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index
2021-01-0183
PREAI
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
2020-11-05161
OAAI
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events
2020-03-0195
PREAI
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study
2020-01-0711
OAAI